Impact of human immunodeficiency virus on the severity of Buruli ulcer disease: Results of a retrospective study in cameroon

Open Forum Infectious Diseases

Volumn 1, Issue 1, 2014, Pages

  Christinet, Vanessa ^a,b   Comte, Eric ^b   Ciaffi, Laura ^a,b   Odermatt, Peter ^c,d   Serafini, Micaela ^b   Antierens, Annick ^b   Rossel, Ludovic ^b   Nomo, Alain Bertrand ^b   Nkemenang, Patrick ^b   Tsoungui, Akoa ^e   Delhumeau, Cecile ^a   Calmy, Alexandra ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

^e Akonolinga District Hospital   (Cameroon)

Author keywords

Buruli ulcer; Cameroon; HIV; Mycobacterium ulcerans disease

Indexed keywords

ADULT; ARTICLE; BODY MASS; BURULI ULCER; CAMEROON; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84939237570     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu021     Document Type: Article

References (39)

1. Boulkroun S, Guenin-Mace L, Thoulouze MI, et al. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 2010; 184:1436-4.
2. Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol 2009; 27:291-305.
3. Agbenorku P. Multicenter study of Buruli ulcer disabilities in the head and neck region. Plast Surg Int 2011; 2011:647418.
4. Adle-Biassette H, Huerre M, Breton G, et al. [Non tuberculous mycobacterial diseases]. Ann Pathol 2003; 23:216-35.
5. World Health Organization. Buruli ulcer epidemiology. Wkly Epidemiol Rec 2009; 84:41-8.
6. Merritt RW, Walker ED, Small PL, et al. Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 2010; 4: e911.
7. Van der Werf TS, Stienstra Y, Johnson RC, et al. Mycobacterium ulcerans disease. Bull World Health Org 2005; 83:785-91.
8. Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg 2008; 102:969-98.
9. Raghunathan PL, Whitney EA, Asamoa K, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): results from a casecontrol study in Ghana. Clin Infect Dis 2005; 40:1445-53.
10. Herbinger KH, Adjei O, Awua-Boateng NY, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis 2009; 48:1055-64.
11. Portaels F, Johnson P, Meyers WM. Buruli ulcer-Diagnosis of Mycobacterium Ulcerans disease. Geneva: WHO; 2001.
12. World Health Organization. Buruli ulcer disease. Geneva: WHO; 2007. Available at: http://www.who.int/mediacentre/factsheets/fs199/en/. Accessed April 1, 2014.
13. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375:664-72.
14. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: WHO; 2011. Available at: http://www.who.int/buruli/information/antibiotics/en/. Accessed 1 April 2014.
15. World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013. Available at: http://www.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1. Accessed April 1, 2014].
16. Johnson RC, Nackers F, Glynn JR, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008; 22:901-3.
17. Darie H, Cautoclaud A, Lajaunie C, Millet P. [Dermatological aspects of AIDS in western Africa. Apropos of 140 cases]. Bull Soc Pathol Exot 1994; 87:176-80.
18. Johnson RC, Ifebe D, Hans-Moevi A, et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS 2002; 16:1704-5.
19. Kibadi K, Colebunders R, Muyembe-Tamfum JJ, et al. Buruli ulcer lesions in HIV-positive patient. Emerg Infect Dis 2010; 16:738-9.
20. Toll A, Gallardo F, Ferran M, et al. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol 2005; 30:649-51.
21. Sopoh GE, Dossou AD, Brun LV, et al. Severe multifocal form of Buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Am J Trop Med Hyg 2010; 83:307-13.
22. Portaels F, Zinsou C, Aguiar J, et al. Les atteintes osseuses dans l'ulcère de Buruli: A propos de 73 cas. Bull Séanc Acad R Sci Outre-Mer 2003; 49:161-90.
23. Ouattara D, Meningaud JP, Saliba F. [Multifocal forms of Buruli ulcer: clinical aspects and management difficulties in 11 cases]. Bull Soc Pathol Exot 2002; 95:287-91.
24. O'Brien DP, Robson ME, Callan PP, et al. "Paradoxical" immunemediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191:564-6.
25. Schutte D, Um-Boock A, Mensah-Quainoo E, et al. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 2007; 1:e2.
26. Gooding TM, Johnson PD, Campbell DE, et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun 2001; 69:1704-7.
27. Gooding TM, Johnson PD, Smith M, et al. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002; 70:5562-7.
28. Lagarrigue V, Portaels F, Meyers WM, et al. [Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin]. Med Trop 2000; 60:262-6.
29. Noeske J, Kuaban C, Rondini S, et al. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 2004; 70:520-6.
30. Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62-5.
31. Phillips R, Sarfo FS, Guenin-Mace L, et al. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis 2009; 200: 1675-84.
32. Prasad R. Pulmonary sarcoidosis and chronic cutaneous atypical mycobacter ulcer. Aust Fam Physician 1993; 22:755-8.
33. Bahebeck J, Bedimo R, Eyenga V, et al. (2004) The management of musculoskeletal infection in HIV carriers. Acta Orthop Belg 2004; 70: 355-60.
34. Delaporte E, Savage C, Alfandari S, et al. [Buruli ulcer in a Zairian woman with HIV infection]. Ann Dermatol Venereol 1994; 121: 557-60.
35. Porten K, Sailor K, Comte E, et al. Prevalence of Buruli ulcer in Akonolinga health district, Cameroon: results of a cross sectional survey. PLoS Negl Trop Dis 2009; 3:e466.
36. DHS. Cameroon Demographic and Health Survey and Multiple Indicators Cluster Survey (DHS-MICS). 2011. Available at: http://www.measuredhs.com/pubs/pdf/HF42/HF42.pdf. Accessed 1 April 2014.
37. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and metaanalysis. PLoS Med 2012; 9:e1001270.
38. Laterali M. Ethnographie de la constitution d'un problème de santé publique au Cameroun: l'exemple de l'ulcère de Buruli ou atom dans l'arrondissement d'Ayos [MD Thesis]. Neuchâtel: University of Neuchâtel. 2005; 157-62. Available at: http://books.google.ch/books/about/Ethnographie_de_la_constitution_d_un_pro.html?id=FivmkQEACAAJ&redir_esc=y.
39. Jacobsen KH, Padgett JJ. Risk factors for Mycobacterium ulcerans infection. Int J Infect Dis 2010; 14:e677-81.